Both FHTX and LCTX operate in the high-risk, high-reward field of clinical-stage biotechnology, where pipeline news and partnership decisions can drive dramatic swings in valuation. This stock comparison is relevant for traders and investors who track speculative healthcare names, monitor relative performance, and weigh near-term catalysts against longer-term scientific potential. The two companies pursue different therapeutic approaches — Foghorn focuses on oncology and chromatin biology, while Lineage develops "off-the-shelf" cell replacement therapies — yet both face the shared challenge of converting early-stage science into clinical and commercial value amid limited revenue and evolving market sentiment.
Foghorn Therapeutics is a clinical-stage biotechnology company that develops medicines targeting the chromatin regulatory system, a key mechanism controlling gene expression. Its proprietary "Gene Traffic Control" platform underpins programs in oncology and immunology. In recent weeks, the company's market positioning deteriorated significantly. Foghorn and Eli Lilly announced they would not advance FHD-909, a Phase 1 SMARCA2-targeting candidate, into clinical expansion, and the companies ceased further collaboration activity on the SMARCA2 degrader program. Foghorn responded by cutting approximately 40% of its workforce and refocusing resources on wholly owned programs, extending its projected cash runway into the second half of 2029.
The news triggered a sharp sell-off, and several analysts lowered ratings and price targets. The stock now trades near the lower end of its 52-week range, and its market capitalization has contracted to a small-cap level. Relative performance has been weak, with the shares down materially on both a year-to-date and one-year basis. Investor sentiment has shifted from speculative optimism to concern about the company's reduced pipeline breadth and reliance on early-stage assets.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or "off-the-shelf," cell therapies designed to replace or repair damaged cells and tissue. Its most advanced program, OpRegen, targets geographic atrophy (advanced dry age-related macular degeneration, or AMD) and is partnered with Genentech/Roche. The broader pipeline includes OPC1 for spinal cord injury, the preclinical COR1 corneal program, and the ReSonance hearing-loss program, among others.
Recent market activity has been comparatively constructive. The company provided an update on its ReSonance program, noting completed preclinical milestones and a scheduled regulatory meeting, and secured a patent related to its AlloSCOPE manufacturing platform. Analyst coverage remains favorable, with a consensus "Strong Buy" rating and price targets well above current levels. Although the stock has pulled back from earlier highs and trades near the lower portion of its 52-week range, its year-to-date performance has been stronger than Foghorn's, and its diversified, partially partnered pipeline provides multiple potential catalysts.
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader library of hundreds of AI trading bots that collectively monitor thousands of tickers. Each bot operates with its own trading style, strategy, timeframe, performance history, and watchlist, so no single approach fits every market condition. The "Trending" section is designed to surface the robots currently best aligned with prevailing market dynamics, helping users compare quantitative signals across names like FHTX and LCTX. Exploring Trending AI Robots can offer a data-driven complement to fundamental research.
The clearest contrast between the two companies is catalyst quality. Foghorn's near-term story was substantially disrupted by the end of a high-profile partnership and the discontinuation of its lead candidate, forcing a strategic reset. Lineage, by comparison, retains a partner-backed lead program and a wider set of independent development efforts. Both companies remain pre-profitability and carry clinical and financing risk, but Foghorn's recent restructuring and securities-related investigations introduce additional headline and legal uncertainty.
On market sentiment, Foghorn has faced downgrades and declining price targets, while Lineage has maintained a "Strong Buy" consensus with substantial implied upside. In terms of sector exposure, Foghorn is concentrated in oncology and immunology, whereas Lineage spans ophthalmology, neurology, and other cell-therapy applications. For momentum-oriented traders, Foghorn's collapse reflects broken trend structure, while Lineage's higher-beta but more balanced setup presents a different risk-reward profile.
Based on observable factors — trend consistency, the presence of near-term catalysts, relative stability, and market positioning — Tickeron's AI framework would likely favor LCTX in this comparison. Lineage's partner-supported lead program, diversified pipeline, and constructive analyst stance contrast with Foghorn's recent pipeline setback, workforce reduction, and deteriorating sentiment. While both names remain high-risk clinical-stage biotechs, the AI verdict leans toward the stock with more intact trend structure and a more balanced catalyst profile. This assessment is probabilistic in nature and is not intended as investment advice.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for FHTX moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 57 cases where FHTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHTX as a result. In 68 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.370) is normal, around the industry mean (3.498). P/E Ratio (-1.889) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FHTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where LCTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 100 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
LCTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FHTX | LCTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 73 | |
P/E GROWTH RATING 1..100 | 8 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FHTX's Valuation (23) in the null industry is in the same range as LCTX (26). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
FHTX's Profit vs Risk Rating (100) in the null industry is in the same range as LCTX (100). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
LCTX's SMR Rating (98) in the null industry is in the same range as FHTX (100). This means that LCTX’s stock grew similarly to FHTX’s over the last 12 months.
FHTX's Price Growth Rating (65) in the null industry is in the same range as LCTX (73). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
FHTX's P/E Growth Rating (8) in the null industry is in the same range as LCTX (34). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
| FHTX | LCTX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | N/A |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 83% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 86% | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 88% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 84% |
| Advances ODDS (%) | 26 days ago 86% | 7 days ago 76% |
| Declines ODDS (%) | 10 days ago 84% | 3 days ago 83% |
| BollingerBands ODDS (%) | 3 days ago 83% | 3 days ago 89% |
| Aroon ODDS (%) | 5 days ago 87% | 3 days ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FHTX’s FA Score shows that 2 FA rating(s) are green while LCTX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FHTX’s TA Score shows that 5 TA indicator(s) are bullish while LCTX’s TA Score has 4 bullish TA indicator(s).
FHTX (@Biotechnology) experienced а +10.70% price change this week, while LCTX (@Biotechnology) price change was -10.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
FHTX is expected to report earnings on Mar 11, 2027.
LCTX is expected to report earnings on Mar 11, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with IMTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then IMTX could also see price increases.
| Ticker / NAME | Correlation To FHTX | 1D Price Change % | ||
|---|---|---|---|---|
| FHTX | 100% | +0.98% | ||
| IMTX - FHTX | 42% Loosely correlated | -1.99% | ||
| ARVN - FHTX | 41% Loosely correlated | -0.73% | ||
| IMVT - FHTX | 41% Loosely correlated | -2.48% | ||
| BNTC - FHTX | 39% Loosely correlated | -0.55% | ||
| BEAM - FHTX | 38% Loosely correlated | -4.99% | ||
More | ||||
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | -7.64% | ||
| EDIT - LCTX | 44% Loosely correlated | +1.40% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.51% | ||
| IMNM - LCTX | 41% Loosely correlated | +0.37% | ||
| FHTX - LCTX | 41% Loosely correlated | +0.98% | ||
| VIR - LCTX | 40% Loosely correlated | -17.82% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MAGA | 57.19 | N/A | N/A |
| Truth Social America First ETF (MAGA) | |||
| HJUN | 25.34 | N/A | N/A |
| Corgi U.S. Equities 100% Structured Buffer ETF - June Series (HJUN) | |||
| VRIG | 25.06 | -0.01 | -0.04% |
| Invesco Variable Rate Investment Grade ETF (VRIG) | |||
| GDE | 50.80 | -0.26 | -0.51% |
| WisdomTree Efficient Gold Plus Equity Strategy Fund (GDE) | |||
| GXPT | 31.15 | -0.57 | -1.80% |
| Global X PureCap MSCI Information Technology ETF (GXPT) | |||